Greg  Keenan net worth and biography

Greg Keenan Biography and Net Worth

Chief Medical Officer of Aurinia Pharmaceuticals

Greg Keenan, MD, joined Aurinia in 2023 as Chief Medical Officer. Dr. Keenan is an experienced physician who has played key roles in Phase 1 through Phase 4 clinical development of over 19 products, including small and large molecules as well as gene therapies across numerous therapeutic areas as well as numerous orphan and rare diseases. 

Most recently, he was the Chief Medical Officer at ValenzaBio, an early-stage biotech company developing biologic treatments for a variety of autoimmune and inflammatory diseases.  Prior to that he was Senior Vice President, Global Head of Medical and Drug Safety at Avrobio, a gene therapy company. Previously he served as Vice President, U.S., Medical Affairs and Head Medical Officer at AstraZeneca, which he joined following the company’s acquisition of Medimmune.  Earlier, he held roles of increasing responsibility at Human Genome Sciences Inc., and at Johnson and Johnson’s Centocor subsidiary.

Dr. Keenan began his career as a rheumatologist in academia, holding appointments at The Hospital of the University of Pennsylvania and the Children’s Hospital of Pennsylvania. He completed fellowships in pediatric and adult rheumatology at the University of Pennsylvania after having completed his residency in medicine/pediatrics at the LA County/University of Southern California Medical Center. Dr. Keenan holds an M.D. from Albany Medical College and a B.A. from Colby College.

What is Greg Keenan's net worth?

The estimated net worth of Greg Keenan is at least $1.23 million as of March 7th, 2025. Dr. Keenan owns 153,484 shares of Aurinia Pharmaceuticals stock worth more than $1,234,011 as of March 31st. This net worth evaluation does not reflect any other investments that Dr. Keenan may own. Learn More about Greg Keenan's net worth.

How do I contact Greg Keenan?

The corporate mailing address for Dr. Keenan and other Aurinia Pharmaceuticals executives is 4464 MARKHAM STREET SUITE 1203, VICTORIA A1, V8Z 7X8. Aurinia Pharmaceuticals can also be reached via phone at 250-708-4272 and via email at ir@auriniapharma.com. Learn More on Greg Keenan's contact information.

Has Greg Keenan been buying or selling shares of Aurinia Pharmaceuticals?

Over the course of the past ninety days, Greg Keenan has sold $166,262.15 of Aurinia Pharmaceuticals stock. Most recently, Greg Keenan sold 8,305 shares of the business's stock in a transaction on Friday, March 7th. The shares were sold at an average price of $8.23, for a transaction totalling $68,350.15. Following the completion of the sale, the insider now directly owns 153,484 shares of the company's stock, valued at $1,263,173.32. Learn More on Greg Keenan's trading history.

Who are Aurinia Pharmaceuticals' active insiders?

Aurinia Pharmaceuticals' insider roster includes Jeffrey Bailey (Director), Matthew Donley (VP), Peter Greenleaf (CEO), Scott Habig (Chief Commercial Officer), Joseph Hagan (Director), Robert Huizinga (EVP), David Jayne (Director), Greg Keenan (Chief Medical Officer), Jill Leversage (Director), Michael Martin (Insider), Joseph Miller (CFO), and Neil Solomons (Insider). Learn More on Aurinia Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Aurinia Pharmaceuticals?

In the last twelve months, insiders at the biotechnology company sold shares 7 times. They sold a total of 366,704 shares worth more than $2,888,411.85. The most recent insider tranaction occured on March, 7th when insider Greg Keenan sold 8,305 shares worth more than $68,350.15. Insiders at Aurinia Pharmaceuticals own 4.3% of the company. Learn More about insider trades at Aurinia Pharmaceuticals.

Information on this page was last updated on 3/7/2025.

Greg Keenan Insider Trading History at Aurinia Pharmaceuticals

See Full Table

Greg Keenan Buying and Selling Activity at Aurinia Pharmaceuticals

This chart shows Greg Keenan's buying and selling at Aurinia Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$166ksoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$100k$0$100kTotal Insider BuyingTotal Insider Selling

Aurinia Pharmaceuticals Company Overview

Aurinia Pharmaceuticals logo
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.
Read More

Today's Range

Now: $8.04
Low: $7.93
High: $8.23

50 Day Range

MA: $8.09
Low: $7.55
High: $8.67

2 Week Range

Now: $8.04
Low: $4.71
High: $10.67

Volume

1,474,687 shs

Average Volume

1,348,234 shs

Market Capitalization

$1.10 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.26